Psychoactive fungi

Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin

Retrieved on: 
Wednesday, October 7, 2020

The provisional patent application covers, among other things, an enhancer that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects.

Key Points: 
  • The provisional patent application covers, among other things, an enhancer that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects.
  • NeuroPharm is a developer of natural health, psilocybin-based treatments for PTSD and mental health disorders in the veteran community.
  • Josh Bartch, CEO of Mydecine, commented: The invention covered by this exciting provisional patent filing holds great promise for the treatment of a range of psychiatric disorders.
  • For further information about Mydecine Innovations Group Inc., please consult the Company's profile on SEDAR at www.sedar.com or visit the Company's website at http://mydecine.com/.

Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications

Retrieved on: 
Thursday, October 1, 2020

Sansero Life Sciences , a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin.

Key Points: 
  • Sansero Life Sciences , a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin.
  • The research agreement between Sansero and the University of Toronto is an important step in expanding the companys pharmaceutical product development program.
  • Sansero is focused on developing pharmaceuticals that include a minimal effective dose (MED) of psilocybin in combination with other naturally-sourced ingredients.
  • Sansero Life Sciences is a leader in compliant cultivation, formulation, research and development of psilocybin-based therapeutic products.

Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory

Retrieved on: 
Thursday, September 24, 2020

Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.

Key Points: 
  • Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.
  • Under its Health Canada licence for the production and extraction of psilocybin from mushrooms, Numinus intends to cultivate and harvest the mushrooms for a variety of purposes including:
    "We are thrilled to start growing mushrooms at our laboratory under our Health Canada licence," says Michael Tan, Chief Operating Officer.
  • Numinus' vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated.
  • Numinus' ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health.

Cybin Corp. CEO Discusses Ongoing Efforts to Develop One of the First Commercially Approved Psychedelic Medications for Mental Health

Retrieved on: 
Tuesday, September 15, 2020

Were developing mushroom-derived pharmaceuticals for mental illness also health products from mushrooms that support areas like cognition and immune response.

Key Points: 
  • Were developing mushroom-derived pharmaceuticals for mental illness also health products from mushrooms that support areas like cognition and immune response.
  • Through our sublingual psilocybin development program, we are in position to hopefully be among the first commercially approved psychedelic medications for mental health, he said.
  • For the past dozen years or so, Ive been the CEO of three different companies.
  • When speaking about the impact of the ongoing COVID-19 pandemic, Drysdale detailed how Cybin has been able to avoid many of the associated business hurdles.

Rritual™ Announces Suite of Premium Functional Mushroom and Adaptogenic Elixirs

Retrieved on: 
Wednesday, September 9, 2020

VANCOUVER, BC, Sept. 9, 2020 /PRNewswire/ -- Rritual , the premium brand in the emerging functional mushroom market, announced today that it will launch its suite of premium mushroom and adaptogen enhanced elixirs this fall.

Key Points: 
  • VANCOUVER, BC, Sept. 9, 2020 /PRNewswire/ -- Rritual , the premium brand in the emerging functional mushroom market, announced today that it will launch its suite of premium mushroom and adaptogen enhanced elixirs this fall.
  • Synergistic adaptogenic herbs and botanicals are also included to enhance the benefits of each mushroom and create balanced elixirs that nourish the body, mind and spirit.
  • Recent data from Food Navigator shows an 800% demand increase for key mushroom varieties, with demand currently outstripping supply.
  • Rritual makes premium plant-based elixir products in small batches featuring mindfully-selected medicinal mushrooms and adaptogenic herbs.

Cybin Applauds TheraPsil’s Advocacy to Bring Psilocybin Therapy to Palliative Care of Canadian Patients

Retrieved on: 
Friday, August 7, 2020

They are also the first known patients to legally use psilocybin since the compound became illegal in Canada in 1974.

Key Points: 
  • They are also the first known patients to legally use psilocybin since the compound became illegal in Canada in 1974.
  • This is a watershed moment for the patients involved who deserve the right to manage their health challenges with dignity, said Paul Glavine, Co-founder of Cybin.
  • Everyone at Cybin applauds the efforts of TheraPsil and these brave individuals, and we thank the Minister of Health for her foresight.
  • I joined Cybin because of their dedication to patients who need and benefit from psilocybin-assisted therapy."

Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent

Retrieved on: 
Monday, July 27, 2020

TORONTO, July 27, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma (Mindset), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a provisional patent application with the USPTO for a groundbreaking process to synthesize psilocybin and psilocintwo of the known active compounds in psychedelic mushrooms.

Key Points: 
  • TORONTO, July 27, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma (Mindset), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a provisional patent application with the USPTO for a groundbreaking process to synthesize psilocybin and psilocintwo of the known active compounds in psychedelic mushrooms.
  • Currently, high-quality psilocybin for research purposes is expensive and difficult to procure.
  • We believe that our innovative synthesis process will enable the widespread adoption of Mindsets standard psilocybin.
  • This patent filing is a significant milestone for Mindset.

New Poll shows large majority of Canadians approve of legal access to Psilocybin for terminally-ill patients; TheraPsil urges Health Minister to respond to Dying Canadians and align with public opinion

Retrieved on: 
Tuesday, June 23, 2020

Given that mushrooms have been illegal for decades, its amazing that 59% of Canadians approve of compassionate access for the terminally ill.

Key Points: 
  • Given that mushrooms have been illegal for decades, its amazing that 59% of Canadians approve of compassionate access for the terminally ill.
  • I believe that our laws are clearly unaligned with science and public opinion, said Spencer Hawkswell, Executive Director at TheraPsil.
  • We are encouraged to see that the more Canadians learn about psilocybin, the more the public is accepting of this treatment option, and support it.
  • The results of this poll validate the discrepancy between current policy regarding psilocybin mushrooms and the Canadian publics opinion on their medical value.

Positive First Steps Show the Promise of Psychedelic Therapies

Retrieved on: 
Wednesday, June 10, 2020

For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .

Key Points: 
  • For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .
  • Just like with cannabis and CBD products, legalization efforts will be spread to both the national and local levels.
  • Such a wide scope of applications is also anticipated to further expand the target demographic of the market.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Positive First Steps Show the Promise of Psychedelic Therapies

Retrieved on: 
Wednesday, June 10, 2020

For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .

Key Points: 
  • For example, back in 2019, Denver voters approved some of the nation's first legal protections for psychedelic mushroom users, according to the Denver Post .
  • Just like with cannabis and CBD products, legalization efforts will be spread to both the national and local levels.
  • Such a wide scope of applications is also anticipated to further expand the target demographic of the market.
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.